CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Lyell Immunopharma
Company Type: Therapeutic development
Main focus: Developing CAR T-cell therapies to treat various cancers
Company stage: Clinical
Diseases: Aggressive B-cell Non-hodgkin lymphoma and other malignancies
Genome-editing tool: CRISPR-Cas9
Funding stage: Series C
Location: South San Francisco, California, USA
Website: lyell.com
Pipeline: lyell.com/our-pipeline
Partners:
Lyell Immunopharma is a clinical-stage biotechnology company focused on the development of CAR T-cell therapies to advance their use in cancer treatment. The company has developed multiple genetic and epigenetic T-cell reprogramming technologies to overcome limitations set by current cell therapies. These involve genetically engineering T cells using CRISPR-Cas9 technology to target c-Jun overexpression and knockout of NR4A3. Lyell’s proprietary epigenetic reprogramming platforms, Epi-R™ and Stim-R™, aim to enhance T-cell mediated anti-tumour activity through epigenetic editing of T-cell therapeutics.
